A rare case of isoniazid induced sideroblastic anemia

Arjun B. Hari; Kunal Chawla; Rishikesh Dessai; Shipra Gulati

doi:10.18203/2320-6012.ijrms20232448

Authors

Arjun B. Hari Department of Family Medicine, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Rajinder Nagar, New Delhi, India
Kunal Chawla Department of Medicine, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Rajinder Nagar, New Delhi, India
Rishikesh Dessai Department of Medicine, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Rajinder Nagar, New Delhi, India
Shipra Gulati Department of Medicine, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Rajinder Nagar, New Delhi, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20232448

Keywords:

Antitubercular treatment, Isoniazid, Pyridoxine, Sideroblastic anemia

Abstract

Sideroblastic anemia is a rare cause of anemia. Most of it accounts for the genetic cause, while drug induced is still uncommon. Our patient, a 20 year old female, is a known case of right frontal tuberculoma on ATT presented with complaints of generalized weakness and loss of appetite. On evaluation, she was found to have severe anemia and bone marrow studies confirmed it to be sideroblastic anemia. On revisiting the history, it was noted that she was not taking pyridoxine supplements as advised along with antitubercular drugs. Our patient is one among the few documented cases of Isoniazid induced sideroblastic anemia.This case needs attention because it is a preventable cause of anemia and the clinicians need to be aware about the compliance of the patient with the supplementary drugs.

Metrics

Metrics Loading ...

References

Ducamp S, Fleming MD. The molecular genetics of sideroblastic anemia. Blood. 2019;133(1):59-69.

Bottomley SS, Fleming MD. Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin North Am. 2014;28(4):653-70.

Yoshimoto S, Takeuchi M, Tada A. Secondary sideroblastic anemia caused by long term administration of anti-tuberculous agents including isoniazid. Rinsho Ketsueki. 1992;33(7):986-90.

Singh T. Atlas and text of hematology. 4th ed. New Delhi: Avichal Publishing Company; 2020: 203-205.

Colucci G, Silzle T, Solenthaler M. Pyrazinamide-induced sideroblastic anemia. Am J Hematol. 2012;87(3):305.

Morse BS, Guiliani D, Minak V, Nussbaum M. Abnormal erythroid maturation in mice induced by isoniazid. Blood. 1975;46(4):625-9.

Berilla EJ, Breydo L, Gouya L, Puy H, Uversky VN, Ferreira GC. Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients. Biochim Biophys Acta Mol Basis Dis. 2017;1863(2):428-39.

Harriss EB, Macgibbon BH, Mollin DL. Experimental sideroblastic anaemia. Br J Haematol. 1965;11:99-106.

Piso RJ, Kriz K, Desax MC. Severe isoniazid related sideroblastic anemia. Hematol Rep. 2011;3(1):e2.

Haden HT. Pyridoxine-responsive sideroblastic anemia due to antituberculous drugs. Arch Intern Med. 1967;120(5):602-6.